Upgrade to SI Premium - Free Trial

Rhythm Pharmaceuticals (RYTM) PT Raised to $133 at Stifel

May 5, 2026 10:44 AM
Stifel analyst Paul Matteis raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $133.00 (from $131.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change